| dbo:abstract |
Istradefyllin ist ein Arzneistoff aus der Gruppe der Psychopharmaka zur Behandlung von Morbus Parkinson. (de) Istradefylline, sold under the brand name Nourianz, is a medication used as an add-on treatment to levodopa/carbidopa in adults with Parkinson's disease (PD) experiencing "off" episodes. Istradefylline reduces "off" periods resulting from long-term treatment with the antiparkinson drug levodopa. An "off" episode is a time when a patient's medications are not working well, causing an increase in PD symptoms, such as tremor and difficulty walking. Relatively common side effects include involuntary muscle movements (dyskinesia), constipation, hallucinations, dizziness and, much like its parent molecule caffeine, nausea and sleeplessness. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. (en) |
| dbo:alternativeName |
Nouriast, Nourianz (en) |
| dbo:casNumber |
155270-99-8 |
| dbo:chEMBL |
431770 |
| dbo:drugbank |
DB11757 |
| dbo:fdaUniiCode |
2GZ0LIK7T4 |
| dbo:kegg |
D04641 |
| dbo:pubchem |
5311037 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Istradefylline.svg?width=300 |
| dbo:wikiPageExternalLink |
https://druginfo.nlm.nih.gov/drugportal/name/istradefylline |
| dbo:wikiPageID |
16878846 (xsd:integer) |
| dbo:wikiPageLength |
9834 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1096176342 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Caffeine dbr:Carbidopa dbr:Dopamine_receptor_D2 dbr:Dyskinesia dbc:Alkene_derivatives dbc:Phenol_ethers dbc:Xanthines dbr:Oral_administration dbr:Management_of_Parkinson's_disease dbr:Receptor_antagonist dbc:Adenosine_receptor_antagonists dbr:Adenosine dbr:Food_and_Drug_Administration dbr:Parkinson's_disease dbr:Protein_dimer dbr:Adenosine_A2a_receptor dbr:Heterotetramer dbr:Dopamine dbr:CYP1A1 dbr:CYP3A4 dbr:CYP3A5 dbr:First-in-class_medication dbr:Striatum dbr:Levodopa dbr:Negative_allosteric_modulator |
| dbp:atcPrefix |
N04 (en) |
| dbp:atcSuffix |
CX01 (en) |
| dbp:c |
20 (xsd:integer) |
| dbp:casNumber |
155270 (xsd:integer) |
| dbp:chembl |
431770 (xsd:integer) |
| dbp:chemspiderid |
4470574 (xsd:integer) |
| dbp:dailymedid |
Istradefylline (en) |
| dbp:drugbank |
DB11757 (en) |
| dbp:eliminationHalfLife |
-248400.0 |
| dbp:excretion |
68 (xsd:integer) |
| dbp:h |
24 (xsd:integer) |
| dbp:iupacName |
8 (xsd:integer) |
| dbp:iupharLigand |
5608 (xsd:integer) |
| dbp:kegg |
D04641 (en) |
| dbp:legalUs |
Rx-only (en) |
| dbp:metabolism |
Mainly CYP1A1, CYP3A4, and CYP3A5 (en) |
| dbp:n |
4 (xsd:integer) |
| dbp:o |
4 (xsd:integer) |
| dbp:proteinBound |
98.0 |
| dbp:pubchem |
5311037 (xsd:integer) |
| dbp:routesOfAdministration |
dbr:Oral_administration |
| dbp:smiles |
O=C2NCC (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
IQVRBWUUXZMOPW-PKNBQFBNSA-N (en) |
| dbp:synonyms |
KW-6002 (en) |
| dbp:tradename |
Nouriast, Nourianz (en) |
| dbp:unii |
2 (xsd:integer) |
| dbp:verifiedrevid |
443805396 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:Adenosinergics dbt:Antiparkinson_agents dbt:Cite_web dbt:Infobox_drug dbt:Portal_bar dbt:Reflist dbt:Short_description dbt:Stimulants dbt:Use_dmy_dates dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Ebicite dbt:Fdacite dbt:Keggcite dbt:Stdinchicite dbt:Drugs.com |
| dcterms:subject |
dbc:Alkene_derivatives dbc:Phenol_ethers dbc:Xanthines dbc:Adenosine_receptor_antagonists |
| gold:hypernym |
dbr:Antagonist |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatMolecularFormulas yago:WikicatUreas yago:WikicatXanthines yago:Abstraction100002137 yago:AliphaticCompound114601294 yago:Alkene114713120 yago:Base114618253 yago:Chemical114806838 yago:Communication100033020 yago:Compound114818238 yago:Element114840755 yago:Formula106816935 yago:Material114580897 yago:Matter100020827 yago:Message106598915 yago:MolecularFormula106817173 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Purine114706749 yago:Quintessence114847103 yago:Relation100031921 yago:Xanthine115113050 dbo:Drug yago:Statement106722453 yago:Substance100019613 yago:Urea115085472 yago:WikicatAlkenes yago:WikicatPhenolEthers yago:WikicatPurines umbel-rc:DrugProduct |
| rdfs:comment |
Istradefyllin ist ein Arzneistoff aus der Gruppe der Psychopharmaka zur Behandlung von Morbus Parkinson. (de) Istradefylline, sold under the brand name Nourianz, is a medication used as an add-on treatment to levodopa/carbidopa in adults with Parkinson's disease (PD) experiencing "off" episodes. Istradefylline reduces "off" periods resulting from long-term treatment with the antiparkinson drug levodopa. An "off" episode is a time when a patient's medications are not working well, causing an increase in PD symptoms, such as tremor and difficulty walking. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. (en) |
| rdfs:label |
Istradefyllin (de) Istradefylline (en) |
| owl:sameAs |
freebase:Istradefylline yago-res:Istradefylline wikidata:Istradefylline dbpedia-de:Istradefylline dbpedia-sh:Istradefylline dbpedia-sr:Istradefylline https://global.dbpedia.org/id/547KT |
| prov:wasDerivedFrom |
wikipedia-en:Istradefylline?oldid=1096176342&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Istradefylline.svg |
| foaf:isPrimaryTopicOf |
wikipedia-en:Istradefylline |
| is dbo:wikiPageRedirects of |
dbr:KW-6002 dbr:Nourianz dbr:C20H24N4O4 |
| is dbo:wikiPageWikiLink of |
dbr:KW-6002 dbr:Nourianz dbr:SCH-58261 dbr:Purinergic_signalling dbr:C20H24N4O4 dbr:Adenosine_A2A_receptor dbr:Adenosine_A2A_receptor_antagonist dbr:Adenosine_receptor dbr:Parkinson's_disease dbr:ATC_code_N04 dbr:List_of_drugs:_Iq–Iv |
| is foaf:primaryTopic of |
wikipedia-en:Istradefylline |
